Citius Pharmaceuticals Inc [NASDAQ: CTXR] closed the trading session at $0.81.
The stocks have a year to date performance of 6.48 percent and weekly performance of -3.32 percent. The stock has been moved at 9.73 percent over the last six months. The stock has performed 8.43 percent around the most recent 30 days and changed 7.40 percent over the most recent 3-months.
If compared to the average trading volume of 751.18K shares, CTXR reached to a volume of 6317105 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Here’s what leading stock market gurus have to say about Citius Pharmaceuticals Inc [CTXR]:
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for CTXR shares is $4.00 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on CTXR stock is a recommendation set at 1.00. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
Maxim Group have made an estimate for Citius Pharmaceuticals Inc shares, keeping their opinion on the stock as Buy, with their previous recommendation back on November 30, 2021.
The Average True Range (ATR) for Citius Pharmaceuticals Inc is set at 0.09 The Price to Book ratio for the last quarter was 1.51, with the Price to Cash per share for the same quarter was set at 0.13.
CTXR stock trade performance evaluation
Citius Pharmaceuticals Inc [CTXR] fell into the red zone at the end of the last week, falling into a negative trend and dropping by -3.32. With this latest performance, CTXR shares gained by 8.43% in over the last four-week period, additionally plugging by 9.73% over the last 6 months – not to mention a drop of -51.18% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for CTXR stock in for the last two-week period is set at 47.77, with the RSI for the last a single of trading hit 44.94, and the three-weeks RSI is set at 49.49 for Citius Pharmaceuticals Inc [CTXR]. The present Moving Average for the last 50 days of trading for this stock 0.7866, while it was recorded at 0.7849 for the last single week of trading, and 0.8168 for the last 200 days.
Citius Pharmaceuticals Inc [CTXR]: An insightful look at the core fundamentals
Citius Pharmaceuticals Inc’s liquidity data is similarly interesting compelling, with a Quick Ratio of 5.06 and a Current Ratio set at 5.06.
Citius Pharmaceuticals Inc [CTXR]: Institutional Ownership
The top three institutional holders of CTXR stocks are: VANGUARD GROUP INC with ownership of 1.32 billion shares, which is approximately 8.4983%. BLACKROCK INC., holding 1.04 billion shares of the stock with an approximate value of $200.69 billion in CTXR stocks shares; and BERKSHIRE HATHAWAY INC, currently with $174.35 billion in CTXR stock with ownership which is approximately 5.8386%.
